tiprankstipranks
Advertisement
Advertisement

EYPT Stock Latest News

EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
The FlyEyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
2d ago
EYPT
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
PremiumCompany Announcements
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
2d ago
8K
EYPT
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
PremiumCompany Announcements
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
8d ago
EYPT
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
PremiumRatings
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
9d ago
EYPT
EyePoint reports Q1 EPS (99c), consensus (81c)
PremiumThe Fly
EyePoint reports Q1 EPS (99c), consensus (81c)
9d ago
EYPT
EYPT Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsEYPT Upcoming Earnings Report: What to Expect?
12d ago
EYPT
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
Premium
Weekend Updates
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
21d ago
AGX
EYPT
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
Premium
Company Announcements
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
1M ago
8K
EYPT
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
PremiumCompany Announcements
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
2M ago
8K
EYPT
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
PremiumCompany Announcements
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
2M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
2M ago
EYPT
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
PremiumRatings
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
2M ago
EYPT
EyePoint price target raised to $35 from $31 at Citi
PremiumThe FlyEyePoint price target raised to $35 from $31 at Citi
2M ago
EYPT
EyePoint Pharma Bets Big on DuraVu in Pivotal Push
Premium
Company Announcements
EyePoint Pharma Bets Big on DuraVu in Pivotal Push
2M ago
EYPT
EyePoint price target raised to $30 from $23 at H.C. Wainwright
Premium
The Fly
EyePoint price target raised to $30 from $23 at H.C. Wainwright
2M ago
EYPT
EyePoint price target raised to $29 from $27 at Chardan
PremiumThe Fly
EyePoint price target raised to $29 from $27 at Chardan
2M ago
EYPT
EyePoint reports Q4 EPS (81c), consensus (75c)
PremiumThe Fly
EyePoint reports Q4 EPS (81c), consensus (75c)
2M ago
EYPT
EyePoint expects cash to fund operations into Q4 2027
PremiumThe Fly
EyePoint expects cash to fund operations into Q4 2027
2M ago
EYPT
EyePoint Starts Global Phase 3 Trials for DURAVYU
PremiumCompany Announcements
EyePoint Starts Global Phase 3 Trials for DURAVYU
2M ago
8K
EYPT
EyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU
PremiumThe FlyEyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU
2M ago
EYPT
Is EYPT a Buy, Before Earnings?
Premium
Pre-Earnings
Is EYPT a Buy, Before Earnings?
2M ago
EYPT
EyePoint price target raised to $36 from $33 at Mizuho
Premium
The Fly
EyePoint price target raised to $36 from $33 at Mizuho
3M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >